Virilization and metabolic disease in postmenopausal women related to ovarian hyperplasia and hypertecosis
DOI:
https://doi.org/10.31053/1853.0605.v78.n2.32136Keywords:
virilism, diabetes insipidus, thecomaAbstract
During menopausal transition, mild clinical signs of hyperandrogenism may appear as part of the normal aging process, but the development of frank virilization suggests a specific source of androgen excess. In this context, androgen-secreting tumors at both adrenal and ovarian levels should be ruled out.
We present the case of a 51-year-old postmenopausal woman with signs of 12 month period virilization, associated with personal history of type 2 diabetes and arterial hypertension, poorly managed in the past year. Laboratory tests showed elevation of serum androgen levels and hyperinsulinemia. Images were requested, revealing both enlarged homogeneous and solid ovaries, with preserved adrenal glands, which led to suspicion of a possible thecal hyperplasia of the ovarian stroma. Laparoscopic bilateral adnexectomy was performed and the pathological report confirmed the presumptive diagnosis. One month later after surgery, serum testosterone levels returned to values close to spected for a postmenopausal woman.
Finding the source of virilization in postmenopausal women is challenging, and they are usually associated with rare pathologies. A detailed medical history is essential to differentiate the progressive development of virilization that characterizes benign causes from the rapid progression that characterizes malignant tumors. The adequate interpretation of laboratory tests with complementary images, as well as looking for the association of pathologies causing elevated cardiovascular risk such as diabetes and hypertension are essential to establish a right diagnosis and treatment.
Downloads
References
Alpañés M, González-Casbas JM, Sánchez J, Pián H, Escobar-Morreale HF. Management of postmenopausal virilization. J Clin Endocrinol Metab. 2012 Aug;97(8):2584–8.
Yance VRV, Marcondes JAM, Rocha MP, Barcellos CRG, Dantas WS, Avila AFA, et al. Discriminating between virilizing ovary tumors and ovary hyperthecosis in postmenopausal women: clinical data, hormonal profiles and image studies. Eur J Endocrinol. 2017 Jul;177(1):93–102.
Brown DL, Henrichsen TL, Clayton AC, Hudson SBA, Coddington CC 3rd, Vella A. Ovarian stromal hyperthecosis: sonographic features and histologic associations. J Ultrasound Med. 2009 May;28(5):587–93.
Elhassan YS, Idkowiak J, Smith K, Asia M, Gleeson H, Webster R, et al. Causes, Patterns, and Severity of Androgen Excess in 1205 Consecutively Recruited Women. Vol. 103, The Journal of Clinical Endocrinology & Metabolism. 2018. p. 1214–23.
Araque TL, Ortiz IRM, González JEM, García AJ, Hidalgo IN, Gamarra VA, et al. Ovarian Stromal Hyperplasia: A Rare Cause of Postmenopausal Hyperandrogenism. Vol. 26, Journal of Menopausal Medicine. 2020. p. 39.
Sharabidze N, Burkadze G, Sabakhtarashvili M. Cell adhesion and apoptosis in ovarian stromal hyperplasia and hyperthecosis. Georgian Med News. 2006 Feb;(131):33–7.
Castell A-L, Hieronimus S, Chevallier A, Sadoul J-L, Galand-Portier M-B, Delotte J, et al. [Post-menopausal ovarian hyperthecosis]. Vol. 40, Gynécologie Obstétrique & Fertilité. 2012. p. 316–9. French.
Nagamani M, Hannigan EV, Dinh TV, Stuart CA. Hyperinsulinemia and stromal luteinization of the ovaries in postmenopausal women with endometrial cancer. J Clin Endocrinol Metab. 1988 Jul;67(1):144–8.
Kim Y, Marjoniemi V-M, Diamond T, Lim A, Davis G, Murrell D. Androgenetic alopecia in a postmenopausal woman as a result of ovarian hyperthecosis. Vol. 44, Australasian Journal of Dermatology. 2003. p. 62–6.
Ashawesh K, Aghilla MM, Randeva HS. Androgenic alopecia in postmenopausal ovarian hyperthecosis. J Obstet Gynaecol. 2011 May;31(4):351–2.
Leedman PJ, Bierre AR, Martin FIR. Virilizing nodular ovarian stromal hyperthecosis, diabetes mellitus and insulin resistance in a postmenopausal woman. Case report. Vol. 96, BJOG: An International Journal of Obstetrics and Gynaecology. 1989. p. 1095–8.
Barth JH, Jenkins M, Belchetz PE. Ovarian hyperthecosis, diabetes and hirsuties in post-menopausal women. Clin Endocrinol . 1997 Feb;46(2):123–8.
Bühler-Christen A, Tischler V, Diener P-A, Brändle M. New onset alopecia and hirsutism in a postmenopausal women. Vol. 25, Gynecological Endocrinology. 2009. p. 324–7.
Nagamani M, Stuart CA. Specific binding sites for insulin-like growth factor I in the ovarian stroma of women with polycystic ovarian disease and stromal hyperthecosis. Am J Obstet Gynecol. 1990 Dec;163(6 Pt 1):1992–7.
Pascale MM, Pugeat M, Roberts M, Rousset H, Déchaud H, Dutrieux-Berger N, et al. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours. Clin Endocrinol . 1994 Nov;41(5):571–6.
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Faculty of Medical Sciences Journal (RFCM) subscribes to the Open Access policy and does not charge authors fees for publishing, nor does it charge readers fees for accessing published articles (APC).
